Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.

ABSTRACT: Dopamine (DA) replacement therapy continues to be the gold standard treatment for Parkinson's disease (PD), as it improves key motor symptoms including bradykinesia and gait disturbances. With time, treatment induces side effects in the majority of patients, known as L-DOPA-induced dyskinesia (LID), which are often studied in animals by the use of unilateral, toxin-induced rodent models. In this study, we used the progressive, genetic PD model MitoPark to specifically evaluate bilateral changes in motor behavior following long-term L-DOPA treatment at three different stages of striatal DA depletion. Besides locomotor activity, we assessed changes in gait with two automated gait analysis systems and the development of dyskinetic behavior. Long-term treatment with a moderate, clinically rele

SUBMITTER: Gellhaar S 

PROVIDER: S-EPMC4405092 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature